M. Mueser
Impact in
- Oncology top 0.5%
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
-
- Lung Cancer Treatments and Mutations 13
- Gastric Cancer Management and Outcomes 4
- Oncology 15
- Colorectal Cancer Treatments and Studies 14
- Cancer Treatment and Pharmacology 6
- Lung Cancer Research Studies 2
- HER2/EGFR in Cancer Research 2
- Co-authors
- Eric Van Cutsem (4 shared papers)Yves Humblet (3 shared papers)Harry Bleiberg (1 shared paper)Armando Santoro (1 shared paper)Ian Chau (1 shared paper)A. Harstrick (1 shared paper)Chris Verslype (1 shared paper)Salvatore Siena (1 shared paper)
In The Last Decade
M. Mueser
17 papers receiving 4.4k citations
M. Mueser's Hit Papers
Peers
Comparison fields: 5 of 86
- Oncology 3.1k
- Hepatology 527
- Otorhinolaryngology 190
- Pulmonary and Respiratory Medicine 1.3k
- Pathology and Forensic Medicine 474
Countries citing papers authored by M. Mueser
This map shows the geographic impact of M. Mueser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Mueser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Mueser more than expected).
Fields of papers citing papers by M. Mueser
This network shows the impact of papers produced by M. Mueser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Mueser. The network helps show where M. Mueser may publish in the future.
Co-authors
The 25 scholars most cited alongside M. Mueser, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer Hit paper breakdown → | 2004 | 3873 |
| 2 | 2005 | 204 | |
| 3 | 2004 | 112 | |
| 4 | 2004 | 77 | |
| 5 | 2005 | 71 | |
| 6 | 2004 | 62 | |
| 7 | 2004 | 44 | |
| 8 | 2004 | 24 | |
| 9 | 2005 | 22 | |
| 10 | 2004 | 18 | |
| 11 | 2003 | 9 | |
| 12 | 2003 | 6 | |
| 13 | 2003 | 4 | |
| 14 | 2003 | 3 | |
| 15 | 2003 | 3 | |
| 16 | 2003 | 2 | |
| 17 | 2004 | 1 | |
| 18 | 2003 | 1 |
About M. Mueser
M. Mueser is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Otorhinolaryngology, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 18 papers that have together received 4.5k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (14 papers), Lung Cancer Treatments and Mutations (13 papers), Cancer Treatment and Pharmacology (6 papers), Head and Neck Cancer Studies (4 papers), Gastric Cancer Management and Outcomes (4 papers), Lung Cancer Research Studies (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Oncology (3.1k citations), Hepatology (527 citations), Otorhinolaryngology (190 citations), Pulmonary and Respiratory Medicine (1.3k citations) and Pathology and Forensic Medicine (474 citations). M. Mueser has collaborated with scholars based in France, Germany and Spain. Frequent co-authors include Eric Van Cutsem, Yves Humblet, Harry Bleiberg, Armando Santoro, Ian Chau, A. Harstrick, Chris Verslype, Salvatore Siena, David Cunningham and David Khayat. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, New England Journal of Medicine, Lung Cancer and European Journal of Cancer Supplements.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.